Atreca (BCEL) Receives a Buy from Brookline Capital Markets
Brookline Capital Markets analyst Kumaraguru Raja maintained a Buy rating on Atreca (BCEL) today and set a price target of $31.00. The company’s shares closed last Thursday at $18.37.
According to TipRanks.com, Raja is a 4-star analyst with an average return of 25.3% and a 48.2% success rate. Raja covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Outlook Therapeutics, and CNS Pharmaceuticals.
Atreca has an analyst consensus of Strong Buy, with a price target consensus of $29.80, implying a 63.2% upside from current levels. In a report issued on February 26, Canaccord Genuity also maintained a Buy rating on the stock with a $33.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.03 and a one-year low of $10.88. Currently, Atreca has an average volume of 234.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA.